Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Aug 26;27(1):329.
doi: 10.1186/s13054-023-04621-4.

Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis

Nina Christine Andersen-Ranberg  1   2 , Marija Barbateskovic  3 , Anders Perner  4   5   6 , Marie Oxenbøll Collet  4   5 , Lone Musaeus Poulsen  7   4 , Mathieu van der Jagt  8 , Lisa Smit  8 , Jørn Wetterslev  4   9 , Ole Mathiesen  7   4   6 , Mathias Maagaard  7
Affiliations
Meta-Analysis

Haloperidol for the treatment of delirium in critically ill patients: an updated systematic review with meta-analysis and trial sequential analysis

Nina Christine Andersen-Ranberg et al. Crit Care. .

Abstract

Background: Haloperidol is frequently used in critically ill patients with delirium, but evidence for its effects has been sparse and inconclusive. By including recent trials, we updated a systematic review assessing effects of haloperidol on mortality and serious adverse events in critically ill patients with delirium.

Methods: This is an updated systematic review with meta-analysis and trial sequential analysis of randomised clinical trials investigating haloperidol versus placebo or any comparator in critically ill patients with delirium. We adhered to the Cochrane handbook, the PRISMA guidelines and the grading of recommendations assessment, development and evaluation statements. The primary outcomes were all-cause mortality and proportion of patients with one or more serious adverse events or reactions (SAEs/SARs). Secondary outcomes were days alive without delirium or coma, delirium severity, cognitive function and health-related quality of life.

Results: We included 11 RCTs with 15 comparisons (n = 2200); five were placebo-controlled. The relative risk for mortality with haloperidol versus placebo was 0.89; 96.7% CI 0.77 to 1.03; I2 = 0% (moderate-certainty evidence) and for proportion of patients experiencing SAEs/SARs 0.94; 96.7% CI 0.81 to 1.10; I2 = 18% (low-certainty evidence). We found no difference in days alive without delirium or coma (moderate-certainty evidence). We found sparse data for other secondary outcomes and other comparators than placebo.

Conclusions: Haloperidol may reduce mortality and likely result in little to no change in the occurrence of SAEs/SARs compared with placebo in critically ill patients with delirium. However, the results were not statistically significant and more trial data are needed to provide higher certainty for the effects of haloperidol in these patients.

Trial registration: CRD42017081133, date of registration 28 November 2017.

Keywords: Antipsychotics; Delirium; Haloperidol; Meta-analysis; Systematic review.

PubMed Disclaimer

Conflict of interest statement

NCAN was the coordinating investigator of the AID-ICU trial. NCAN, OMAT, AP, LMP and JW were part of the steering committee of the AID-ICU trial. JW has been a member of the task force to develop theory and software for TSA at Copenhagen Trial Unit. MOC was primary investigator of the AID-ICU cohort study. MvdJ and LS are the Principal Investigator and Coordinating Investigator of the EuRIDICE trial. AP has received honorarium for advisory board work with Novartis. MM and MB have nothing to declare.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram
Fig. 2
Fig. 2
Forest plot of all-cause mortality in placebo-controlled trials. Forest plot of all-cause mortality in placebo-controlled trials. Three trials were at overall low risk of bias, and two trials were at overall high risk of bias. Size of the squares reflects the size of the trial (sample size). The horizontal bars represent 96.7% confidence intervals
Fig. 3
Fig. 3
Trial sequential analysis of all-cause mortality in placebo-controlled trials. Trial sequential analysis of all-cause mortality for placebo-controlled trials (3 trials at overall low risk of bias and 2 trials at overall high risk of bias). We used a control event proportion of 38.6%, α of 3.3% (two-sided), β of 10% (power of 90%), diversity of 20% and a priori relative risk reduction or increase (RRR/RRI) of 20%. The z-curve (blue line) did not cross the trial sequential boundaries for benefit or harm (red outward sloping lines) or the inner-wedge futility line (red inward sloping red lines). The green dashed line shows the conventional boundaries for benefit/harm (alpha 0.033)
See this image and copyright information in PMC

References

    1. Association AP. Diagnostic and statistical manual of mental disorders, Fifth edition. American Psychiatric Association; 2013. p. 991.
    1. Krewulak KD, et al. Incidence and prevalence of delirium subtypes in an adult ICU: a systematic review and meta-analysis. Crit Care Med. 2018;46(12):2029–2035. - PubMed
    1. Salluh JI, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015;350:h2538. - PMC - PubMed
    1. Brummel NE, et al. Delirium in the ICU and subsequent long-term disability among survivors of mechanical ventilation. Crit Care Med. 2014;42(2):369–377. - PMC - PubMed
    1. Pandharipande PP, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306–1316. - PMC - PubMed